Maia Biotechnology, Inc. Announces $6.2 Million Financing To Advance Targeted Immuno-Oncology Studies
Amount Raised
$6.2 Million
Round Type
Funding Round
ChicagoBiotechnologyHealth CareScience And EngineeringMedicalTherapeuticsDescription
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that it has raised an additional $6.2 million in an equity offering at $8/share. The proceeds of the financing will advance the company’s programs and will support the initiation of a Phase 2 clinical trial (THIO-101) evaluating the administration of THIO followed by cemiplimab in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The THIO-101 trial is expected to begin this year.
Quick answer
MAIA Biotechnology raised $6.2 Million in a Funding Round round, dated October 14, 2021. MAIA Biotechnology is based in Chicago, Illinois, United States.
- How much did MAIA Biotechnology raise?
- MAIA Biotechnology raised $6.2 Million in a Funding Round round on October 14, 2021.
- What does MAIA Biotechnology do?
- MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend..
- Where is MAIA Biotechnology based and how big is it?
- MAIA Biotechnology is based in Chicago, Illinois, United States.
- Who are the decision-makers at MAIA Biotechnology?
- Fundz holds 2 contacts at MAIA Biotechnology, including the Senior Director, Human Resources. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Medical around the same time
Companies in the same sectors as MAIA Biotechnology that raised within 45 days of this round, from Fundz verified event records.
- Acrivon Therapeutics raised $100M on November 23, 2021.
- Compugen raised $20M on November 22, 2021.
- Acrivon Therapeutics raised $100M (Series B) on November 11, 2021.
- Chase Therapeutics Corporation raised $20M (Series B) on October 20, 2021.
- Lysogene raised $4.6M (Seed) on November 26, 2021.
- Synnovation Therapeutics, Inc. raised $15M on November 26, 2021.
Who to call at MAIA Biotechnology, and when
A new round usually means MAIA Biotechnology is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day MAIA Biotechnology raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at MAIA Biotechnology, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at MAIA Biotechnology. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment MAIA Biotechnology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
MAIA Biotechnology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.